James Niedel serves as a Managing Director at New Leaf Venture Partners. See sector focus and contact routes.
James Niedel serves as a Managing Director at New Leaf Venture Partners, a healthcare technology venture firm he co-founded in 2005 after moving from Sprout Ventures where he was a venture partner since 2002. His investment thesis centers on biopharmaceuticals, healthcare technology, and medical devices, with New Leaf specifically targeting later-stage biopharmaceutical products, early-stage medical devices, and laboratory infrastructure technologies. While specific check sizes and lead/follow behavior are not publicly detailed for Niedel individually, the firm invests across debt, early-stage, and late-stage ventures. Notable portfolio companies include Intarcia Therapeutics, which was highlighted in a press release regarding healthcare technology venture investing. Niedel brings distinctive scientific credibility to his investing, having previously served as Chief Science and Technology Officer for GlaxoSmithKline and as a Professor of Medicine at Duke Medical School. He holds both an M.D. and a Ph.D. in Biochemistry, is a Searle Scholar, and serves on the Scientific Advisory Board of the Tri-Institutional Therapeutics Discovery Institute.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in New York.
Investors like James Niedel · Full investor directory · Investor access · Company funding database